CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) announces its participation in two upcoming virtual investor conferences in March 2021. The Barclays Global Healthcare Conference will take place on March 9, 2021, at 10:20 a.m. ET, and the 33rd Annual Roth Conference is scheduled for March 15, 2021, at 1:30 p.m. ET. Investors can access live webcasts through the company's website, with replay available for 14 days post-event. CRISPR Therapeutics is a leader in gene editing, developing transformative medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

ZUG, Switzerland and CAMBRIDGE, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in March:

Barclays Global Healthcare Conference
Date: Tuesday, March 9, 2021
Time: 10:20 a.m. ET

33^rd Annual Roth Conference
Date: Monday, March 15, 2021
Time: 1:30 p.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
WCG on behalf of CRISPR
+1-617-337-4167
reides@wcgworld.com

FAQ

When is CRISPR Therapeutics participating in the Barclays Global Healthcare Conference?

CRISPR Therapeutics will participate in the Barclays Global Healthcare Conference on March 9, 2021, at 10:20 a.m. ET.

What is the date and time for CRISPR Therapeutics' appearance at the Roth Conference?

The 33rd Annual Roth Conference featuring CRISPR Therapeutics will be held on March 15, 2021, at 1:30 p.m. ET.

How can I watch the CRISPR Therapeutics investor conferences?

Live webcasts of the CRISPR Therapeutics investor conferences can be accessed on the company's website under the 'Events & Presentations' section.

What technology does CRISPR Therapeutics utilize for gene editing?

CRISPR Therapeutics uses the CRISPR/Cas9 platform for precise gene editing to develop transformative gene-based medicines for serious diseases.

How long will the webcasts of CRISPR Therapeutics' presentations be available?

The webcasts of CRISPR Therapeutics' presentations will be archived for 14 days following each event.